Show simple item record

dc.contributor.authorGhidini, M
dc.contributor.authorHahne, JC
dc.contributor.authorFrizziero, M
dc.contributor.authorTomasello, G
dc.contributor.authorTrevisani, F
dc.contributor.authorLampis, A
dc.contributor.authorPassalacqua, R
dc.contributor.authorValeri, N
dc.date.accessioned2018-11-27T15:19:13Z
dc.date.issued2018-08
dc.identifier.citationTargeted oncology, 2018, 13 (4), pp. 423 - 436
dc.identifier.issn1776-2596
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2957
dc.identifier.eissn1776-260X
dc.identifier.doi10.1007/s11523-018-0580-3
dc.description.abstractReceptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling cascades, and as such are involved in a broad variety of cellular functions including differentiation, proliferation, migration, invasion, angiogenesis, and survival under physiological as well as pathological conditions. Aberrant RTK activation can lead to benign proliferative conditions as well as to various forms of cancer. Indeed, more than 70% of the known oncogene and proto-oncogene transcripts involved in cancer code for RTKs. Consequently, these receptors are broadly studied as targets in the treatment of different tumours, and a large variety of small-molecule tyrosine kinase inhibitors (TKIs) are approved for therapy. In most cases, patients develop resistance to the TKIs within a short time. MicroRNAs are short (18-22 nucleotides) non-protein-coding RNAs that fine-tune cell homeostasis by controlling gene expression at the post-transcriptional level. Deregulation of microRNAs is common in many cancers, and increasing evidence exists for an important role of microRNAs in the development of resistance to therapies, including TKIs. In this review we focus on the role of microRNAs in mediating resistance to small-molecule TKIs in solid tumours.
dc.formatPrint
dc.format.extent423 - 436
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectMicroRNAs
dc.subjectProtein Kinase Inhibitors
dc.titleMicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.
dc.typeJournal Article
dcterms.dateAccepted2018-08-01
rioxxterms.versionofrecord10.1007/s11523-018-0580-3
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTargeted oncology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNot known
icr.researchteamEvolutionary Genomics & Modellingen_US
icr.researchteamGastrointestinal Cancer Biology and Genomicsen_US
dc.contributor.icrauthorHahne, Jensen
dc.contributor.icrauthorLampis, Andreaen
dc.contributor.icrauthorValeri, Nicolaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record